The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
复制标题
DOI：
10.3389/fimmu.2022.1088886
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
免疫检查点抑制剂（Immuno-checkpoint inhibitors，ICI）通过增强抗肿瘤活性抑制肿瘤细胞的生长，为癌症患者带来了广阔的前景。然而，并非所有患者都受益于ICI单药治疗。ICIs的部分反应或抵抗主要是由于复杂和异质性的肿瘤微环境（TME）。联合治疗是提高肿瘤治疗效果的必要手段。据报道，化疗不仅可以直接杀死肿瘤细胞，而且可以刺激有效的抗肿瘤免疫反应。ICI和化疗药物的几种联合疗法已被批准用于癌症的一线治疗，包括PD-1/PD-L1抑制剂。本文综述了ICIs和化疗药物联合治疗诱导免疫原性细胞死亡（ICD）和重编程TME的潜在机制，并从代谢重编程和微生物组重编程的角度阐明了联合治疗可能的抗肿瘤作用。
Immuno-checkpoint inhibitors (ICIs) bring a promising prospect for patients with cancers, which restrains the growth of tumor cells by enhancing anti-tumor activity. Nevertheless, not all patients benefit from the administration of ICIs monotherapy. The partial response or resistance to ICIs is mainly due to the complex and heterogenous tumor microenvironment (TME). The combined therapy is necessary for improving the efficacy of tumor treatment. Chemotherapy is reported not only to kill tumor cells directly, but also to stimulate effective anti-tumor immune responses. Several combined therapies of ICIs and chemotherapeutic agents have been approved for the first-line treatment of cancers, including PD-1/PD-L1 inhibitors. This review summarizes the potential mechanisms of the combined therapy of ICIs and chemotherapeutic agents in inducing immunogenic cell death (ICD) and reprogramming TME, and elucidates the possible anti-tumor effects of combined therapy from the perspective of metabolic reprogramming and microbiome reprogramming.
登录
查看更多内容
影响因子：
4.7
作者：
Chen R;Huang M;Yang X;Chen XH;Shi MY;Li ZF;Chen ZN;Wang K
通讯作者：
Wang K
影响因子：
29
作者：
Cascone T;McKenzie JA;Mbofung RM;Punt S;Wang Z;Xu C;Williams LJ;Wang Z;Bristow CA;Carugo A;Peoples MD;Li L;Karpinets T;Huang L;Malu S;Creasy C;Leahey SE;Chen J;Chen Y;Pelicano H;Bernatchez C;Gopal YNV;Heffernan TP;Hu J;Wang J;Amaria RN;Garraway LA;Huang P;Yang P;Wistuba II;Woodman SE;Roszik J;Davis RE;Davies MA;Heymach JV;Hwu P;Peng W
通讯作者：
Peng W
影响因子：
50.3
作者：
Duraiswamy J;Turrini R;Minasyan A;Barras D;Crespo I;Grimm AJ;Casado J;Genolet R;Benedetti F;Wicky A;Ioannidou K;Castro W;Neal C;Moriot A;Renaud-Tissot S;Anstett V;Fahr N;Tanyi JL;Eiva MA;Jacobson CA;Montone KT;Westergaard MCW;Svane IM;Kandalaft LE;Delorenzi M;Sorger PK;Färkkilä A;Michielin O;Zoete V;Carmona SJ;Foukas PG;Powell DJ Jr;Rusakiewicz S;Doucey MA;Dangaj Laniti D;Coukos G
通讯作者：
Coukos G
影响因子：
4.4
作者：
Djenidi, Faycal;Adam, Julien;Mami-Chouaib, Fathia
通讯作者：
Mami-Chouaib, Fathia
影响因子：
7.7
作者：
Barrett RL;Puré E
通讯作者：
Puré E